Stay updated on IGN002 Dose-Escalation Study in NHL Clinical Trial
Sign up to get notified when there's something new on the IGN002 Dose-Escalation Study in NHL Clinical Trial page.

Latest updates to the IGN002 Dose-Escalation Study in NHL Clinical Trial page
- Check5 days agoChange DetectedThe record displays details for the Phase 1 IGN002 study in non-Hodgkin lymphoma, including its terminated status, eligibility criteria, study design, locations, and outcome measures.SummaryDifference36%

- Check12 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAn NIH-wide banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence,” and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe footer now displays site revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check54 days agoChange DetectedAccess to the study page is blocked with a 403 Forbidden error, replacing the record content. The error page obscures the study details and navigation that were previously visible.SummaryDifference16%

- Check61 days agoChange DetectedThe page’s Revision line was updated from v3.6.6 to v3.7.0, signaling a newer version of the page. This appears to be a versioning or content update rather than a change to study results, eligibility, or participation details.SummaryDifference0.1%

Stay in the know with updates to IGN002 Dose-Escalation Study in NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IGN002 Dose-Escalation Study in NHL Clinical Trial page.